AGIOS PHARMACEUTICALS, INC.
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
Agios Pharmaceuticals develops and markets therapies for rare diseases, focusing on cellular metabolism, including treatments for genetic hemolytic anemias such as pyruvate kinase deficiency and thalassemia.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Gheuens SarahChief Medical Officer | Sell | $296K | 7,866at $37.69 | Oct 26, 2026 |
| Gheuens SarahChief Medical Officer | Sell | $56K | 1,489at $37.53 | Oct 21, 2026 |
| Gheuens SarahChief Medical Officer | Sell | $19K | 500at $37.52 | Oct 22, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
| Member | Chamber | Type | Amount | Date |
|---|---|---|---|---|
| Gilbert CisnerosCA31 | House | Buy | $1,001 - $15,000 | Aug 20, 2026 |
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable AGIO activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.